Enzymatic Research Having Pharmaceutical Significance

Author(s):  
Ishan H. Raval ◽  
Arvind Kumar Singh Chandel

The enzymes' biocatalysts act by lowering the activation energy without getting consumed in the reaction. The immense number of enzymes acts as a correctly matched orchestra to ensure that enormously complex life mechanisms and processes occur in a right direction. Sufficient quantity and accurate function of enzymes results in proper functional maintenance of body. The enzymes play a major role in the diagnosis, curing, biochemical investigation, and monitoring of many dreaded diseases of the century. The development of recombinant DNA technology had a significant impression on production levels of enzymes. Around 50% of the enzyme market is covered by recombinant enzymes. Because of development in molecular biology tools, several pharmaceutically enzymes have been identified and are being actively used in the pharmaceutical industry either for diagnostic or treatment. Information on this topic is very insufficient, and thus, the present chapter is an attempt to compile information on the sources, properties and applications of important therapeutic enzymes.

1991 ◽  
Vol 10 (1) ◽  
pp. 18-25
Author(s):  
D. I. Ferreira

Conventional plant breeding has made a significant impact on the increase in crop production during the last half century. Several shortcomings however, opened up the opportunities for the application of biotechnology in plant breeding. The vari­ous approaches in the field of cell biology (tissue culture) and molecular biology (recombinant DNA technology) are dis­cussed and the application thereof is advocated in a global approach to plant breeding.


1988 ◽  
pp. 41-50
Author(s):  
Brian M. Martin ◽  
Shoji Tsuji ◽  
Mary E. LaMarca ◽  
Kara Maysak ◽  
William Eliason ◽  
...  

1998 ◽  
Vol 72 (2) ◽  
pp. 250-278 ◽  
Author(s):  
Louis Galambos ◽  
Jeffrey L. Sturchio

During the twentieth century, the pharmaceutical industry experienced a series of dramatic changes as developments in science and technology generated new opportunities for innovation. Each of these transitions forced existing firms to develop new capabilities. The authors examine the most recent such transition, the shift to molecular genetics and recombinant DNA technology (1970 to the present), and explain how and why this transformation differed from the previous ones in pharmaceuticals. Small biotech startups played an important role in this transition, and the large pharmaceutical firms that began to enter the field had to develop new strategies for innovation. Two major strategies were adopted by the early movers, all of which created various kinds of alliances with the small biotech businesses. By the mid-1990s, the leading pharmaceutical manufacturers had established significant capabilities in the new field, but they were continuing to work with specialized biotechs in order to innovate across a broad range of therapeutic categories.


Sign in / Sign up

Export Citation Format

Share Document